A multi-center clinical study for professor Caigan's experience in the treatment of chronic atrophic gastritis and precancerous lesions of gastric cancer

注册号:

Registration number:

ITMCTR1900002428

最近更新日期:

Date of Last Refreshed on:

2019-06-28

注册时间:

Date of Registration:

2019-06-28

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

蔡淦教授经验方莪连颗粒治疗慢性萎缩性胃炎胃癌前病变的多中心临床研究

Public title:

A multi-center clinical study for professor Caigan's experience in the treatment of chronic atrophic gastritis and precancerous lesions of gastric cancer

注册题目简写:

English Acronym:

研究课题的正式科学名称:

蔡淦教授经验方莪连颗粒治疗慢性萎缩性胃炎胃癌前病变的多中心临床研究

Scientific title:

A multi-center clinical study for professor Caigan's experience in the treatment of chronic atrophic gastritis and precancerous lesions of gastric cancer

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

18401971400

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR1900024158 ; ChiMCTR1900002428

申请注册联系人:

丛军

研究负责人:

丛军

Applicant:

Cong Jun

Study leader:

Cong Jun

申请注册联系人电话:

Applicant telephone:

+86 13918446063

研究负责人电话:

Study leader's telephone:

+86 13918446063

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

jencongcong@hotmail.com

研究负责人电子邮件:

Study leader's E-mail:

jencongcong@hotmail.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

上海市普安路185号曙光医院行政楼二楼219室 邮编20002

研究负责人通讯地址:

上海市普安路185号曙光医院行政楼二楼219室 邮编200021

Applicant address:

Room 219, 2nd Floor, Administration Building, 185 Pu'an Road, Shanghai

Study leader's address:

Room 219, 2nd Floor, Administration Building, 185 Pu'an Road, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

200021

研究负责人邮政编码:

Study leader's postcode:

200021

申请人所在单位:

上海中医药大学附属曙光医院

Applicant's institution:

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2018-632-61-01

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

上海中医药大学附属曙光医院伦理委员会

Name of the ethic committee:

IRB of Shuguang Hospital Affiliated with Shanghai University of TCM

伦理委员会批准日期:

Date of approved by ethic committee:

1990/1/1 0:00:00

伦理委员会联系人:

耿希

Contact Name of the ethic committee:

Gengxi

伦理委员会联系地址:

上海市浦东新区张衡路528号

Contact Address of the ethic committee:

528 Zhangheng Road, Pudong New Area, Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海中医药大学附属曙光医院

Primary sponsor:

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

上海市普安路185号

Primary sponsor's address:

185 Pu'an Road, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海中医药大学附属曙光医院

具体地址:

普安路185号

Institution
hospital:

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Address:

185 Pu'an Road

经费或物资来源:

上海市科学科学技术委员会

Source(s) of funding:

Shanghai Science and Technology Commission

研究疾病:

慢性萎缩性胃炎胃癌前病变

研究疾病代码:

Target disease:

Chronic atrophic gastritis and Precancerous lesions of gastric cancer

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

通过对莪连颗粒治疗慢性萎缩性胃炎胃癌前病变脾虚瘀热证患者的中医证候、胃镜下病理(萎缩、肠上皮化生、异型增生)、安全性指标等进行评价,为总结优势病种的疗效和安全性提供依据。传承、推广蔡淦名中医的学术思想和诊疗方案。

Objectives of Study:

To evaluate the efficacy and safety of the patients with chronic gastric atrophic gastritis and PLGC by evaluating the TCM syndrome, endoscopic pathology (atrophy, intestinal metaplasia, dysplasia) and safety indicators. Inherit and promote Pro.Caigan's academic thoughts and treatment plan.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)符合西医胃镜和病理诊断标准以及中医辨证诊断标准。 (2)纳入试验前1个月内胃镜检查证实诊断,并未接受过治疗。 (3)年龄18-70岁,男女不限。 (4)受试者知情同意,并签署相关文件。

Inclusion criteria

(1) It meets the criteria for Western medicine gastroscope and pathological diagnosis and the diagnostic criteria for TCM syndrome differentiation. (2) The diagnosis was confirmed by gastroscopy within 1 month before the trial, and no treatment was received. (3) Aged 18-70 years, male or female. (4) Subjects informed consent and signed relevant documents.

排除标准:

(1)合并消化性溃疡、胃粘膜有重度异型增生或病理诊断疑有恶变者。 (2)合并心、脑、肝、肾、肺、血液系统等严重疾患者。 (3)妊娠期、哺乳期或计划妊娠患者。 (4)对本研究所用药物或其成分过敏者。 (5)精神病患者或不能合作者。

Exclusion criteria:

(1) Patients with peptic ulcer, severe dysplasia of the gastric mucosa or pathological diagnosis suspected of malignant transformation. (2) Patients with severe diseases such as heart, brain, liver, kidney, lung and blood system. (3) Patients during pregnancy, lactation or planned pregnancy. (4) Those who are allergic to the drug or its components in this study. (5) Psychiatric patients or those who cannot cooperate.

研究实施时间:

Study execute time:

From 2018-07-01

To      2021-06-30

征募观察对象时间:

Recruiting time:

From 2019-07-01

To      2021-06-30

干预措施:

Interventions:

组别:

胃复春对照治疗组

样本量:

100

Group:

Weifuchun Control Treatment Group

Sample size:

干预措施:

胃复春片和莪连颗粒模拟剂

干预措施代码:

Intervention:

Weifuchun Tablet and E-Lian Granule Simulator

Intervention code:

组别:

莪连颗粒治疗组

样本量:

100

Group:

E-Lian Granule treatment group

Sample size:

干预措施:

莪连颗粒和胃复春片模拟剂

干预措施代码:

Intervention:

E-Lian Granule and Weifuchun Tablet Simulator

Intervention code:

样本总量 Total sample size : 200

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

复旦大学附属华东医院

单位级别:

三级甲等

Institution/hospital:

Huadong Hospital Affiliated to Fudan University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市普陀区中医医院

单位级别:

二级甲等

Institution/hospital:

Shanghai Putuo District Hospital of Traditional Chinese Medicine

Level of the institution:

Secondary A

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海中医药大学附属龙华医院

单位级别:

三级甲等

Institution/hospital:

Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市奉贤区中医医院

单位级别:

二级甲等

Institution/hospital:

Shanghai Fengxian District Hospital of Traditional Chinese Medicine

Level of the institution:

Secondary A

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海中医药大学附属曙光医院

单位级别:

三级甲等

Institution/hospital:

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

尿妊娠试验

指标类型:

附加指标

Outcome:

Urine HCG

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

尿常规检查

指标类型:

次要指标

Outcome:

Urine routine examination

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规

指标类型:

次要指标

Outcome:

Blood test

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

大便常规检查

指标类型:

次要指标

Outcome:

Stool routine examination

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝功能检查

指标类型:

次要指标

Outcome:

Liver function test

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胃镜及病理检查

指标类型:

主要指标

Outcome:

Gastroscopy and Gastric mucosal biopcy

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肾功能检查

指标类型:

次要指标

Outcome:

Kidney function test

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

尿

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后保存

说明

Fate of sample 

Preservation after use

Note:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后保存

说明

Fate of sample 

Preservation after use

Note:

标本中文名:

粪便

组织:

Sample Name:

Stool

Tissue:

人体标本去向

使用后保存

说明

Fate of sample 

Preservation after use

Note:

标本中文名:

胃黏膜

组织:

Sample Name:

Gastric mucosal

Tissue:

人体标本去向

使用后保存

说明

Fate of sample 

Preservation after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大 70
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

统计学专家进行区组随机。

Randomization Procedure (please state who generates the random number sequence and by what method):

premuted block by statistical expert.

盲法:

双盲

Blinding:

Double blind

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

RRDCAP

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

https://www.studyhealth.org:1443/redcap

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF和Redcap收集数据

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF and Redcap

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above